ArticleBreast cancer research : BCR2026
CXCL12/ZNF503/GATA3/MMP1 axis promotes tumor progression and metastasis of triple-negative breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is a subtype of breast cancer which has the poorest prognosis, with high recurrence and metastasis rates. ZNF503 (Zinc finger elbow-related proline domain protein 2) was a transcriptional factor involved in the aggressive breast cancer development through the down-regulation of GATA3 expression. However, the precise role of the ZNF503/GATA3 axis in TNBC progression and metastasis remains unclear.
methodsRT-qPCR and Western blotting were used to investigate the expression profiles of ZNF503 and GATA3 in breast cancer cell lines. Stable cell lines with either gene knockdown or overexpression were subsequently established for mechanistic investigations in vitro and in vivo functional studies. Chromatin immunoprecipitation (ChIP), RT-qPCR, Western blotting, CCK-8, Transwell and immunofluorescence experiments were performed to reveal the molecular mechanisms of CXCL12/ZNF503/GATA3 on TNBC progression. Bioinformatic prediction using UCSC Genome Browser and JASPAR database identified NF-κB as a potential regulator of ZNF503, which was subsequently validated through dual luciferase reporter assays and ChIP experiments. RNA-seq and GO analysis were conducted to screen MMP1 as the downstream molecule. The prognostic value of CXCL12/ZNF503/GATA3/MMP1 was assessed by Kaplan-Meier survival curves and ROC curves analyses.
resultsIn this study, we observed that ZNF503 was highly expressed in TNBC and contributed to TNBC proliferation and metastasis by suppressing GATA3 expression. We further identified that CXCL12 regulated ZNF503/GATA3 expression via the PI3K/Akt/NF-κB signaling pathway, thereby driving TNBC proliferation and metastasis. Additionally, the CXCL12/ZNF503/GATA3 axis promoted TNBC progression by regulating the downstream molecule MMP1. Meanwhile, we suggested that the CXCL12/ZNF503/GATA3/MMP1 signature has the potential to serve as a valuable biomarker for TNBC prognosis.
conclusionsOur findings underscored that the CXCL12/ZNF503/GATA3/MMP1 axis facilitated tumor progression and metastasis of TNBC, thus providing a novel therapeutic strategy for TNBC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.